Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade D 11.72 1.30% 0.15
GLYC closed up 1.3 percent on Friday, May 24, 2019, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical GLYC trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 1.30%
NR7 Range Contraction -1.26%
Inside Day Range Contraction -1.26%
20 DMA Resistance Bearish -0.76%
Fell Below 50 DMA Bearish -0.76%

Older signals for GLYC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Biotechnology Health Pharmaceutical Industry Diseases Chemotherapy Drug Discovery Clinical Trial Acute Myeloid Leukemia Design Of Experiments Product Testing Pseudomonas Sickle Cell Disease Hematologic Cancers Nursing Research
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.99
52 Week Low 8.29
Average Volume 202,618
200-Day Moving Average 12.3946
50-Day Moving Average 12.3686
20-Day Moving Average 12.1895
10-Day Moving Average 12.072
Average True Range 0.6323
ADX 15.4
+DI 13.8107
-DI 24.7045
Chandelier Exit (Long, 3 ATRs ) 11.3031
Chandelier Exit (Short, 3 ATRs ) 13.1369
Upper Bollinger Band 12.976
Lower Bollinger Band 11.403
Percent B (%b) 0.2
BandWidth 12.904549
MACD Line -0.1302
MACD Signal Line -0.0496
MACD Histogram -0.0806
Fundamentals Value
Market Cap 383.51 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -8.75
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.12
Resistance 3 (R3) 12.12 11.98 12.05
Resistance 2 (R2) 11.98 11.88 11.98 12.03
Resistance 1 (R1) 11.85 11.82 11.92 11.85 12.01
Pivot Point 11.72 11.72 11.75 11.72 11.72
Support 1 (S1) 11.58 11.61 11.65 11.59 11.43
Support 2 (S2) 11.45 11.55 11.45 11.41
Support 3 (S3) 11.32 11.45 11.39
Support 4 (S4) 11.32